One third of the world population is infected with tuberculosis (TB), and new infections occur at a rate of one per second. The recent increase in the emergence of drug-resistant strains of Mycobacterium tuberculosis and the dearth of anti-TB drugs is threatening the future containment of TB. New drugs or delivery systems that will stop the spread of TB and slow down or prevent the development of drug-resistant strains are urgently required. One of the reasons for the emergence of drug-resistant strains is the exposure of mycobacteria to sub-therapeutic levels of one or more antibiotics. Lung lesions containing large numbers of bacteria are poorly vascularized and are fortified with thick fibrous tissue; conventional therapy by the oral and parenteral routes may provide sub-therapeutic levels of anti-TB drugs to these highly sequestered organisms. Administering drugs by the pulmonary route to the lungs allows higher drug concentrations in the vicinity of these lesions. Supplementing conventional therapy with inhaled anti-TB therapy may allow therapeutic concentrations of drug to penetrate effectively into lung lesions and treat the resident mycobacteria
Inhaled Drug Delivery for Tuberculosis Therapy
Muttil, P., Wang, CC., & Hickey, A. (2009). Inhaled Drug Delivery for Tuberculosis Therapy. Pharmaceutical Research, 26(11), 2401-2416. https://doi.org/10.1007/s11095-009-9957-4
Abstract
Publications Info
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.
Meet the Experts
View All ExpertsRecent Publications
METHODS REPORT
Improving text classification with Boolean retrieval for rare categories
Article
Use of a web-based portal to return normal individual research results in Early Check
Article
Personal exposure to PM2.5 in different microenvironments and activities for retired adults in two megacities, China
Article